Literature DB >> 33359649

Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.

Xue-Tao Xu1, Jie Chen2, Xiang Ren2, Yu-Ran Ma2, Xiao Wang2, Yan-Yan Ma1, Den-Gao Zhao1, Ren-Ping Zhou3, Kun Zhang1, Susan Goodin4, Dong-Li Li1, Xi Zheng5.   

Abstract

Cancer stem cell (CSC) plays an important role in pancreatic cancer pathogenesis and treatment failure. CSCs are characterized by their ability to form tumor spheres in serum-free medium and expression of CSC related markers. In the present study, we investigated the effect atorvastatin, celecoxib and tipifarnib in combination on proliferation and apoptosis in Panc-1 sphere-forming cells. The sphere-forming cells were isolated from Panc-1 cells by sphere-forming method. These sphere-forming cells showed CSC properties. The levels of CD44, CD133 and ALDH1A1 in the sphere-forming cells were increased. Moreover, Panc-1 sphere-forming cells were resistant to chemotherapeutic drug gemcitabine. Combined atorvastatin with celecoxib and tipifarnib synergistically decreased the sphere forming ability of Panc-1 cells and the drug combination also strongly inhibited cell proliferation and promoted apoptosis in the sphere-forming cells. The effects of the drug combination on the Panc-1 sphere-forming cells were associated with decreases in the levels of CD44, CD133 and ALDH1A1, and suppression of Akt and NF-κB activation. Results of the present study indicate that the combination of atorvastatin, celecoxib and tipifarnib may represent an effective approach for inhibiting pancreatic CSCs.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; Atorvastatin; Celecoxib; Chemoresistant; Pancreatic cancer; Stem cells; Tipifarnib

Mesh:

Substances:

Year:  2020        PMID: 33359649     DOI: 10.1016/j.ejphar.2020.173840

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Atorvastatin inhibits the proliferation of MKN45-derived gastric cancer stem cells in a mevalonate pathway-independent manner.

Authors:  Ye Seul Choi; Hee Jeong Cho; Hye Jin Jung
Journal:  Korean J Physiol Pharmacol       Date:  2022-09-01       Impact factor: 1.718

2.  A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma.

Authors:  Xiao-Mao Tian; Bin Xiang; Yi-Hang Yu; Qi Li; Zhao-Xia Zhang; Chenghao Zhanghuang; Li-Ming Jin; Jin-Kui Wang; Tao Mi; Mei-Lin Chen; Feng Liu; Guang-Hui Wei
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

3.  Celecoxib-Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by 89Zr Immuno-PET.

Authors:  Kyung-Ho Jung; Jin Hee Lee; Mina Kim; Eun Ji Lee; Young Seok Cho; Kyung-Han Lee
Journal:  Mol Imaging       Date:  2022-01-07       Impact factor: 4.488

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.